
    
      Phase I Patients will receive atezolizumab at a fixed dose of 1200 mg intravenously (i.v.)
      followed by PM01183 at a starting dose of 2.5 mg/m2 i.v. as a 1-hour infusion on Day 1 every
      three weeks (q3wk). PM01183 doses will be escalated in successive cohorts of patients
      following a modified Fibonacci scheme and a classical 3+3 design, and according to observed
      tolerance and safety.

      To determine the maximum tolerated dose (MTD) and the recommended dose for phase II studies
      (RD) of PM01183 in combination with atezolizumab in advanced SCLC patients progressing after
      platinum doublet chemotherapy.
    
  